Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@article{Ferm2007ChemotherapyPI,
  title={Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.},
  author={C. Ferm{\'e} and H. Eghbali and J. Meerwaldt and C. Rieux and J. Bosq and F. Berger and T. Girinsky and P. Brice and M. V. van't Veer and J. Walewski and P. Lederlin and U. Tirelli and P. Carde and E. W. Van Den Neste and E. Gyan and M. Monconduit and M. Divin{\'e} and J. Raemaekers and G. Salles and E. Noordijk and G. Creemers and J. Gabarre and A. Hagenbeek and O. Reman and M. Blanc and Jos{\'e} Thomas and B. Vi{\'e} and J. Kluin-Nelemans and F. Viseu and J. Baars and P. Poortmans and P. Lugtenburg and C. Carrie and J. Jaubert and M. Henry-Amar},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 19},
  pages={
          1916-27
        }
}
BACKGROUND Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three… Expand
Treatment of early-stage Hodgkin lymphoma.
TLDR
Here, the European Organization for Research and Treatment of Cancer (EORTC) demonstrated that in positron emission tomography (PET)-positive patients after two cycles of ABVD, treatment switched toTwo cycles of BEACOPPbaseline plus radiotherapy results in significantly improved outcomes. Expand
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
TLDR
This trial investigated whether radiotherapy can be omitted without loss of efficacy in patients who have a complete metabolic response after receiving two cycles of escalated doses of etoposide, cyclophosphamide, and doxorubicin, and whether non-inferiority of the PET4-guided strategy in the 5-year progression-free survival estimates is shown. Expand
Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
TLDR
Although both the RAPID and H10 trials reported poorer disease control without RT, PET-guided omission of RT can constitute a valid therapeutic option in patients with an increased risk of RT-associated toxicity (eg, because of sex, age, or disease localization). Expand
Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
TLDR
The results support the superiority and continued use of CMT, specifically abbreviated-course chemotherapy and involved-field radiotherapy, as an appropriate treatment approach for early-stage Hodgkin's lymphoma. Expand
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
TLDR
Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL. Expand
Radiotherapy in early stage classical Hodgkin lymphoma: past, present and future.
TLDR
For early stage classical Hodgkin lymphoma (HL), extended field irradiation (EFRT) alone has shown excellent results in low relapse rate and high long-term survival rate, and the combined modality therapy (CMT) as the first-line therapy has replaced the radiotherapy (RT) alone. Expand
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
TLDR
In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy. Expand
Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
TLDR
Four cycles of ABVD and reduced dose IFRT resulted in optimal outcomes and there were no in-field relapses in patients with bulky disease receiving RT doses > 25.2 Gy. Expand
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
TLDR
The response-guided ABVD program, based on standard clinical staging procedures, proved to be feasible and safe in patients with intermediate-stage Hodgkin lymphoma. Expand
Therapeutic recommendations for early stage Hodgkin lymphomas
TLDR
Positron emission tomography‐computed tomography (PET‐CT) scanning has emerged as a very important tool for disease staging and end of treatment assessment and was recently evaluated in a randomized clinical trial to evaluate individualized therapy based on PET response after 2 or 3 cycles of ABVD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
TLDR
A treatment strategy for early-stage HL based on prognostic factors leads to high OS rates in both favorable and unfavorable patients, and in favorable patients, the combination of EBVP and IF-RT can replace STNI as standard treatment. Expand
ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
TLDR
Present long-term findings suggest that, after four cycles of ABVD, I FRT can achieve a worthwhile outcome, and ABVD followed by IFRT can be considered an effective and safe modality in early Hodgkin's disease with both favorable and unfavorable presentation. Expand
Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
TLDR
The efficacy of four cycles of ABVD regimen, with suitable dose intensity, and radiotherapy as consolidation therapy, and involved field radiotherapy results were as effective as extended field, without acute toxicity. Expand
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
  • A. Engert, P. Schiller, +17 authors V. Diehl
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Radiotherapy volume size reduction from EF to IF after COPP + ABVD chemotherapy for two cycles produces similar results and less toxicity in patients with early-stage unfavorable HD. Expand
Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
  • S. Laskar, T. Gupta, +5 authors K. Dinshaw
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
It is suggested that the addition of consolidation radiation helps improve the EFS and OS in patients achieving a complete remission after six cycles of ABVD chemotherapy, particularly in the younger age group and in patients with B symptoms and bulky and advanced disease. Expand
Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.
TLDR
The results of this interim analysis can be interpreted as a trend that therapy intensity in combined modality treatment of early stage Hodgkin′s lymphoma might be further reduced in terms of the number of chemotherapy cycles as well as the radiotherapy dose, even in IF-RT setting. Expand
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
  • O. Press, M. Leblanc, +7 authors R. Fisher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
It is demonstrated that it is possible to obtain a high failure-free survival rate in a large group of stage IA to IIA patients without performing staging laparotomy and that three cycles of chemotherapy plus STLI provide a superior FFS compared with STLI alone. Expand
Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
TLDR
LD-IFRT after an initial complete response to risk-adapted chemotherapy improved EFS, but follow-up remains short; at this time, there is no survival advantage for LD-IF RT. Expand
An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
TLDR
This long-term follow-up report supports the initial impression that the MOPP/ABV Hybrid chemotherapy is an effective and well-tolerated program for patients with advanced Hodgkin's disease. Expand
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
TLDR
Although 5-year freedom from disease progression was superior in patients receiving radiation therapy, this advantage is offset by deaths due to causes other than progressive Hodgkin's lymphoma or acute treatment-related toxicity. Expand
...
1
2
3
...